Australis Capital - Folium merger cancelled
Australis Capital announced on 18 February 2020 that the proposed merger with Folium Biosciences would be called off following the discovery of ‘new relevant information with regard to Folium.’ Further details have not been disclosed. Australis previously planned on divesting its THC associated assets, which we now assume will not proceed following the termination of the merger agreement.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.